Improved Lyme Disease Tests Could Reduce US Healthcare Costs by 41%
New analysis suggests that higher-sensitivity testing could lower annual spending by more than $3 billion by reducing misdiagnosis.
New analysis suggests that higher-sensitivity testing could lower annual spending by more than $3 billion by reducing misdiagnosis.
WHO has added the first molecular diagnostic test for Ebola Bundibugyo virus to its Emergency Use Listing, aiming to support rapid infection confirmation and surveillance during the ongoing outbreak in Central Africa.
The facility will support the clinical validation of diagnostic kits that provide results via a mobile app without the need for laboratory processing.
A field-deployable test demonstrates high sensitivity in identifying low-level infections that traditional methods miss, potentially supporting elimination efforts.
The high-throughput host-response assay provides results in approximately 20 minutes to help guide treatment decisions and antimicrobial stewardship.
The PCR test detects 11 bacterial, viral, and parasitic pathogens from a stool sample in approximately 74 minutes.
Research identifies how circulating tumor DNA can inform personalized treatment and surveillance strategies.